瑞康医药(002589) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥1,756,650,456.75, representing a decrease of 12.98% compared to ¥2,018,758,765.18 in the same period last year[5] - Net profit attributable to shareholders was ¥14,171,093.11, down 6.58% from ¥15,168,972.69 year-on-year[5] - The net profit excluding non-recurring gains and losses was ¥10,033,796.54, a significant decline of 44.75% from ¥18,162,174.56 in the previous year[5] - Total operating revenue decreased to ¥1,756,650,456.75 from ¥2,018,758,765.18, representing a decline of approximately 12.96% year-over-year[21] - Total operating costs decreased to ¥1,764,616,859.72 from ¥2,023,237,316.54, a reduction of about 12.77% year-over-year[22] - Net profit increased to ¥19,435,375.87 compared to ¥18,571,098.80, marking an increase of approximately 4.65% year-over-year[22] - The net profit attributable to the parent company was ¥14,171,093.11, down from ¥15,168,972.69, reflecting a decrease of about 6.58% year-over-year[23] - The company reported a basic and diluted earnings per share of ¥0.0094, down from ¥0.0101, a decrease of approximately 6.93%[23] Cash Flow and Liquidity - Operating cash flow improved to ¥43,026,148.76, a remarkable increase of 179.55% compared to a negative cash flow of -¥54,084,542.82 in the same period last year[5] - Cash inflow from operating activities was ¥1,858,405,712.59, down from ¥2,096,078,080.88, indicating a decrease of approximately 11.36% year-over-year[25] - Cash outflow from operating activities totaled 1,913,930,631.99, down from 2,231,248,746.34[26] - Cash inflow from investment activities was 25,039,560.23, a decrease from 106,456,178.96 in the previous period[26] - The company reported a net increase in cash and cash equivalents of 283,319,012.93, compared to 130,806,158.63 previously[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥16,040,336,865.84, reflecting a slight increase of 0.17% from ¥16,012,320,005.02 at the end of the previous year[5] - Total current assets amount to 11,156,915,614.31 CNY, an increase from 11,081,074,502.55 CNY at the beginning of the period[19] - Total liabilities include short-term borrowings of 6,331,689,125.44 CNY, up from 6,091,678,576.33 CNY[19] - Total liabilities increased to ¥10,351,484,097.44 from ¥10,317,701,838.65, a rise of approximately 0.33%[20] - Total equity decreased slightly to ¥5,688,852,768.40 from ¥5,694,618,166.37, a decline of about 0.10%[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 77,616[15] - Zhang Renhua holds 13.39% of shares, totaling 201,498,159 shares, with 90,874,100 shares pledged[15] - Han Xu holds 12.33% of shares, totaling 185,491,897 shares, with 151,100,000 shares pledged[15] Other Income and Expenses - Other income increased by 489.62% to ¥21.58, attributed to higher government subsidies received compared to the previous year[12] - Research and development expenses were ¥2,954,283.92, slightly down from ¥3,103,612.68, a decrease of about 4.80% year-over-year[22] Audit Information - The company did not undergo an audit for the first quarter report[28]